The move: Delta Air Lines slid as much as 11% on Tuesday, hitting $44.5. The stock is down 16.81% for the year Why: The airline slashed its outlook for first-quarter revenue and earnings over ...

Now, economic growth forecasts are moving lower, and strategists are discussing the likelihood that their year-end targets for the S&P 500 might've been too optimistic. "We have seen the US equity ...

21:26 EDT Cathie Wood’s ARK Investment buys 35K shares of Recursion Pharmaceuticals (RXRX) today Effectively assess a stock's risks and opportunities with a clear breakdown of its positive and ...

JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th.

In February, Arrowhead Pharmaceuticals closed a global licensing and collaboration agreement with Sarepta Therapeutics Inc. Arrowhead receives a $500 million upfront payment and $325 million through ...

However, the stock was also likely negatively impacted by CNBC Mad Money host Jim Cramer's comments on Friday. He expressed reservations about buying shares of Recursion Pharmaceuticals in light ...

The brokerage currently has an overweight rating on the biopharmaceutical company’s stock ... sell-side analysts forecast that Lexicon Pharmaceuticals will post -0.66 earnings per share for ...

Costco stock fell more than 6% Friday, after the member-based warehouse retailer reported quarterly revenue and earnings per share that undershot expectations. Get the full story: Costco Revenue ...

Learn More » Here are four things you should know if you're thinking of buying Recursion Pharmaceuticals stock. 1. Early innings of AI-powered biotech Recursion stands out as a pure play in AI ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply ...

Explore Mira Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for MIRA. EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value ...